---
title: "LKPC: The production and sales of the LuKang Tailor Mycin series products are stable"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234205405.md"
description: "LKPC announced the situation of investor research reception, stating that product prices fluctuate with changes in supply and demand, and the same applies to the product of Tylosin. At the same time, price fluctuations are influenced by various factors, which brings uncertainty, and the impact on the company's performance is also uncertain. The company continues to carry out technological iteration and cost reduction to enhance efficiency, continuously improving product competitiveness, and the production and sales of LKPC's Tylosin series products are stable"
datetime: "2025-04-02T10:55:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234205405.md)
  - [en](https://longbridge.com/en/news/234205405.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234205405.md)
generator: "portal-rs"
---

# LKPC: The production and sales of the LuKang Tailor Mycin series products are stable

LKPC announced the situation of investor research reception, stating that product prices fluctuate with changes in supply and demand, and the same applies to Tylosin products. At the same time, price fluctuations are influenced by various factors, which brings uncertainty, and the impact on the company's performance is also uncertain. The company continues to carry out technological iteration and cost reduction to enhance efficiency, continuously improving product competitiveness, and the production and sales of LKPC's Tylosin series products are stable

### Related Stocks

- [600789.CN](https://longbridge.com/en/quote/600789.CN.md)

## Related News & Research

- [Shenzhen Investment Restructures Connected Deals via Property Transfer and Ends Development Pact](https://longbridge.com/en/news/298067700.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**